Alexandre Draznieks appointed CEO of Cardif Lux Vie

Alexandre Draznieks appointed CEO of Cardif Lux Vie


Cardif Lux Vie has announced the appointment of Alexandre Draznieks as its CEO (Managing Director) with effect from September 1, 2022.

Alexandre Draznieks began his career in 1994 at INSEE (National Institute of Statistics and Economic Studies) as a research officer. In 2002, he joined the Treasury Department of the French Ministry of the Economy and Finance as deputy head of "G7 and preparation of summits", then as head of "emerging markets". In 2005, he was appointed to the EBRD (European Bank for Reconstruction & Development, London) where he was in charge of the President's office and then held the position of Director "Official Co-financing ".

He joined the BNP Paribas Group in 2009 at IRB (International Retail Banking), where he was in charge of strategy. In 2012, he becomes head of the Northern Europe & emerging markets area of BNP Paribas Cardif. In 2020, he joined BNP Paribas Cardif France where he was appointed Director of the AEP business unit, a French player in asset-based life insurance. 

Alexandre Draznieks is a graduate of the École Polytechnique de Paris and the École Nationale de la Statistique et de l'Analyse Économique (ENSAE). 

As CEO of Cardif Lux Vie, Alexandre Draznieks will be in charge of the development of the business in Luxembourg and in the countries where the company operates in Europe (France, Italy, Belgium, Spain, Portugal) and outside the European Economic Area. 

"I am delighted to join Cardif Lux Vie and to actively contribute to the development of our business by focusing our actions on innovation, digitalization and service quality. I will also pursue our initiatives to make Cardif Lux Vie a company that is centered on people and that has a positive impact on the environment and society," said Alexandre Draznieks. 

Alexandre Draznieks succeeds Christian Gibot who has been appointed to the Executive Committee of BGL BNP Paribas as Head of Wealth Management. This appointment is subject to the approval of national and European regulatory authorities.